491 results on '"Minotti, Giorgio"'
Search Results
2. Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study
3. Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review
4. Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story
5. Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis
6. The cancer patient and cardiology.
7. Heart Failure in Long-Term Survivors of Childhood or Adolescent Cancers
8. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
9. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
10. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology
11. Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis
12. Acute Heart Failure 29 Years After Treatment for Childhood Cancer
13. LDL Cholesterol and Cardiovascular Events in a Population Network: One More Twist of an Endless Story
14. Sodium–Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials
15. Temporal patterns of left ventricular systolic and diastolic metrics changes in adult patients with haematological malignancies treated with chimeric antigen receptor (CAR)-T cells: results from the CARdio-Tox prospective study
16. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Heart Failure in China: a new pillar in our pockets, but at what price?
17. Anthracyclines and cardiotoxicity: Is CARP a forgotten biomarker?
18. Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock
19. Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
20. A Special Section on Clinical Pharmacology—Editorial
21. Cardiac Imaging in Childhood Cancer Survivors: A State-of-the-Art Review
22. Cardiac Imaging in Childhood Cancer Survivors: A State-of-the-Art Review
23. Temporal patterns of left ventricular systolic and diastolic metrics changes in adult patients with haematological malignancies treated with chimeric antigen receptor (CAR)-T cells: results from the CARdio-Tox prospective study.
24. Correction to: Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab
25. Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab
26. New Targeted Drugs for Acute Myeloid Leukemia and Antifungals: Pharmacokinetic Challenges and Opportunities
27. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion
28. Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study
29. Cardiac Imaging in Childhood Cancer Survivors: A State-of-the-Art Review
30. Ibrutinib and Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death
31. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence
32. What is cardiotoxicity?
33. Cost-Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?
34. Anthracyclins
35. Anthracycline Cardiotoxicity
36. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
37. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
38. Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment–Related Early Diastolic Dysfunction
39. From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction
40. Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox
41. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
42. Risk of Myocardial Infarction in Patients Treated With 5-Fluorouracil
43. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
44. Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases
45. Report and Recommendations of the Workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity
46. Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection
47. Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis
48. Safety and tolerability of a novel oral nutritional supplement in healthy volunteers
49. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
50. An introduction to the metabolic determinants of anthracycline cardiotoxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.